0000000000448828

AUTHOR

Joaquín Gavilá

showing 5 related works from this author

A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuva…

2009

Abstract Background Aromatase (CYP19A1) regulates estrogen biosynthesis. Polymorphisms in CYP19A1 have been related to the pathogenesis of breast cancer (BC). Inhibition of aromatase with letrozole constitutes the best option for treating estrogen-dependent BC in postmenopausal women. We evaluate a series of polymorphisms of CYP19A1 and their effect on response to neoadjuvant letrozole in early BC. Methods We analyzed 95 consecutive postmenopausal women with stage II-III ER/PgR [+] BC treated with neoadjuvant letrozole. Response to treatment was measured by radiology at 4th month by World Health Organization (WHO) criteria. Three polymorphisms of CYP19A1, one in exon 7 (rs700519) and two in…

OncologyCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentAnastrozoleAntineoplastic AgentsBreast Neoplasmslcsh:RC254-282AromataseBreast cancerSurgical oncologyInternal medicineNitrilesGeneticsmedicineHumansAromatase3' Untranslated RegionsNeoadjuvant therapyAgedAged 80 and overPolymorphism GeneticAromatase inhibitorbiologybusiness.industryLetrozoleMiddle AgedTriazoleslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseImmunohistochemistryNeoadjuvant TherapyPostmenopauseTreatment OutcomeEndocrinologyOncologyLetrozoleDisease Progressionbiology.proteinFemalebusinessTamoxifenResearch Articlemedicine.drugBMC Cancer
researchProduct

Physical activity and breast cancer risk by pathological subtype

2017

Abstract Objective To examine the influence of physical activity on breast cancer risk and evaluate whether adherence to international recommendations is associated with a decreased risk. Methods This is a multicenter matched case-control study where 698 pairs completed a physical activity questionnaire. Recreational physical activity during the last year was quantified in metabolic equivalent hours per week (MET-h/week) and categorized in activities of moderate (3.0–5.9 MET) and vigorous (>6 MET) intensity. The adherence to World Cancer Research Fund and the American Institute for Cancer Research recommendation was also assessed. The association with breast cancer risk, overall and by path…

Adultmedicine.medical_specialtyAdolescentPhysical activityBreast NeoplasmsOverweightMetabolic equivalentYoung Adult03 medical and health sciences0302 clinical medicineBreast cancerInternal medicinemedicineHumans030212 general & internal medicineExercisePathologicalAgedMultinomial logistic regressionGynecologybusiness.industryObstetrics and GynecologyMiddle Agedmedicine.diseaseObesityOncologySpainHormone receptorCase-Control Studies030220 oncology & carcinogenesisFemaleGuideline Adherencemedicine.symptombusinessGynecologic Oncology
researchProduct

The effect of obesity on prognosis in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathologic subtyp…

2013

1031 Background: According to observational studies, obesity is an unfavourable prognostic factor in breast cancer (BC), regardless of menopausal status and treatment received. Information collected in clinical trials should confirm this effect and serves to test its homogeneity by pathologic subtype. Methods: We retrospectively analysed 5,683 operable BC patients enrolled in four randomized clinical trials (GEICAM/9906, 9805, 2003–02, and BCIRG 001) evaluating adjuvant anthracyclines and taxanes. Our primary aim was to assess the prognostic effect of body mass index (BMI) on disease recurrence, breast cancer mortality (BCM), and overall mortality (OM). A secondary aim was to detect differ…

GynecologyOncologyCancer Researchmedicine.medical_specialtyPrognostic factorbusiness.industrymedicine.medical_treatmentmedicine.diseaseObesityBreast cancerOncologyInternal medicinemedicineObservational studybusinessAdjuvantJournal of Clinical Oncology
researchProduct

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled…

2013

Obesity is an unfavorable prognostic factor in breast cancer (BC) patients regardless of menopausal status and treatment received. However, the association between obesity and survival outcome by pathological subtype requires further clarification. METHODS: We performed a retrospective analysis including 5,683 operable BC patients enrolled in four randomized clinical trials (GEICAM/9906, GEICAM/9805, GEICAM/2003-02, and BCIRG 001) evaluating anthracyclines and taxanes as adjuvant treatments. Our primary aim was to assess the prognostic effect of body mass index (BMI) on disease recurrence, breast cancer mortality (BCM), and overall mortality (OM). A secondary aim was to detect differences o…

Índice de Masa CorporalOncologyReceptor ErbB-2medicine.medical_treatmentObesidad:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis [Medical Subject Headings]Supervivencia sin EnfermedadBody Mass IndexAntineoplastic Combined Chemotherapy ProtocolsMedicineAnthracyclinesYoung adultMedicine(all)Hazard ratioNeoplasias de la MamaPronósticoFemeninoMiddle AgedPrognosisChemotherapy regimenTreatment OutcomeFemaleTaxoidsMastectomyResearch ArticleAdultmedicine.medical_specialtyAnálisis de Supervivencia:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Body Constitution::Body Weights and Measures::Body Mass Index [Medical Subject Headings]Breast NeoplasmsDisease-Free SurvivalYoung AdultBreast cancerInternal medicineAdjuvant therapyHumansObesity:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Disease-Free Survival [Medical Subject Headings]:Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings]AgedGynecologyDose-Response Relationship Drugbusiness.industry:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [Medical Subject Headings]Retrospective cohort studyAntineoplásicosmedicine.disease:Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings]:Check Tags::Female [Medical Subject Headings]Multivariate Analysis:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings]Neoplasm Recurrence LocalbusinessBody mass index
researchProduct

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

2018

AbstractPurpose: This study aimed to identify biomarkers of resistance to endocrine therapy in estrogen receptor–positive (ER+) breast cancers treated with prolonged neoadjuvant letrozole.Experimental Design: We performed targeted DNA and RNA sequencing in 68 ER+ breast cancers from patients treated with preoperative letrozole (median, 7 months).Results: Twenty-four tumors (35%) exhibited a PEPI score ≥4 and/or recurred after a median of 58 months and were considered endocrine resistant. Integration of the 47 most upregulated genes (log FC > 1, FDR < 0.03) in letrozole-resistant tumors with transcription-binding data showed significant overlap with 20 E2F4-regulated genes (P =…

0301 basic medicineCancer ResearchBreast NeoplasmsE2F4 Transcription FactorArticle03 medical and health sciences0302 clinical medicineText miningDownregulation and upregulationCell Line TumorBiomarkers TumormedicineHumansEndocrine systemProtein Kinase InhibitorsE2F4GeneAgedCell ProliferationAged 80 and overAromatase Inhibitorsbusiness.industryGene Expression ProfilingLetrozoleEndocrine therapyComputational BiologyMiddle AgedEMTREE drug terms: aromatase inhibitorcyclin dependent kinase 4cyclin dependent kinase 6cyclin dependent kinase inhibitorfulvestrantletrozolepaclitaxelpalbociclibtranscription factor E2F4estrogen receptorletrozoleprotein kinase inhibitortranscription factor E2F4transcriptometumor marker030104 developmental biologyReceptors EstrogenOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisLetrozoleMutationRetreatmentCancer researchFemaleTranscriptomebusinessmedicine.drug
researchProduct